Litcius/Paper detail

Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

Ali Hussein Mer, Yousef Mirzaei, Fatemeh Misamogooe, Nader Bagheri, Ahmadreza Bazyari, Zahra Keshtkaran, Anna Meyfour, Alireza Shahedi, Zahra Amirkhani, Ameneh Jafari, Nesa Barpour, Saeed Jahandideh, Behzad Rezaei, Yousef Nikmanesh, Meghdad Abdollahpour‐Alitappeh

2024Drug Delivery and Translational Research28 citationsDOI

Topics & Concepts

MedicineMonoclonal antibodyCancer researchC-MetTyrosine kinaseReceptor tyrosine kinaseCancerAntibody-drug conjugateDrugAntibodyTargeted therapyPharmacologyImmunologyInternal medicineReceptorHepatocyte growth factorLiver physiology and pathologyHER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies | Litcius